TAK
$14.98
Revenue | $1106685Mn |
Net Profits | $124243Mn |
Net Profit Margins | 11.23% |
PE Ratio | 51.62 |
Takeda Pharmaceutical Company Limited’s revenue fell -8.39% since last year same period to $1106685Mn in the Q2 2025. On a quarterly growth basis, Takeda Pharmaceutical Company Limited has generated 5.06% jump in its revenue since last 3-months.
Takeda Pharmaceutical Company Limited’s net profit jumped 30.44% since last year same period to $124243Mn in the Q2 2025. On a quarterly growth basis, Takeda Pharmaceutical Company Limited has generated 220.39% jump in its net profits since last 3-months.
Takeda Pharmaceutical Company Limited’s net profit margin jumped 42.38% since last year same period to 11.23% in the Q2 2025. On a quarterly growth basis, Takeda Pharmaceutical Company Limited has generated 214.59% jump in its net profit margins since last 3-months.
Takeda Pharmaceutical Company Limited’s price-to-earnings ratio after this Q2 2025 earnings stands at 51.62.
EPS Estimate Current Quarter | 0.15 |
EPS Estimate Current Year | 0.15 |
Takeda Pharmaceutical Company Limited’s earning per share (EPS) estimates for the current quarter stand at 0.15 - a -24.73% fall from last quarter’s estimates.
Takeda Pharmaceutical Company Limited’s earning per share (EPS) estimates for the current year stand at 0.15.
Earning Per Share (EPS) | 0 |
Takeda Pharmaceutical Company Limited’s earning per share (EPS) fell -100% since last year same period to 0 in the Q3 2025. This indicates that the Takeda Pharmaceutical Company Limited has generated -100% annual rate of fall in its earning per share (EPS) in the last 4 quarters.
Earnings Date | Estimated EPS | Reported EPS | Surprise % |
---|---|---|---|
2025-07-30 | 0.2 | 151 | 75174.18% |
2025-10-30 | 0.15 | 0 | -100% |
2025-06-25 | -0.17 | -0.23 | -37.11% |